Cardio Diagnostics Announces It’s Exhibiting at the 2024 Onsite Employee Health Clinics Forum

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum, taking place in Chicago, IL, from June 27-28, 2024. The Forum attracts senior executives from various healthcare sectors, including hospitals, health systems, health plans, and employer plans. The event is focused on enabling employers to build, launch, and optimize onsite clinical care facilities that are innovative and effective for their employees.

Employee Onsite Clinics Drive Cost-Savings

The prevalence of onsite clinics is growing, with 53% of large employers offering them in 2023. Employers are finding that convenience for employees and potential cost savings make onsite clinics an attractive benefits option. The ROI is clear for employers. According to Mercer, employers save an average of $1,800 per employee per year after implementing onsite clinics. In addition to the financial savings, employers experience reduced absenteeism and reduce employee reliance on emergency rooms and urgent care clinics.

Cardio Diagnostics' solutions, such as the Epi+Gen CHD heart attack risk assessment test and PrecisionCHD coronary heart disease detection test, are particularly well-suited for deployment at employer onsite clinics. These DNA-based blood tests do not require additional infrastructure from employer organizations, making them an ideal choice for integrating into onsite care models.

HeartRisk: An Employer Disease-Specific Mitigation Platform

The HeartRisk™ platform is the Company’s value-add analytics solution. The HeartRisk risk intelligence platform empowers employers to proactively combat cardiovascular disease in their workforce and mitigate business risks. HeartRisk integrates HIPAA-compliant anonymized and aggregated clinical cardiovascular data from Cardio Diagnostics' Epi+Gen CHD and PrecisionCHD clinical tests, which assess heart attack risk, and current coronary heart disease status, respectively alongside industry and geographic data to provide real-time population-level cardiovascular disease (CVD) risk insights.

Cardio Diagnostics' presence at the 2024 Onsite Employee Health Clinics Forum highlights the critical role of innovative cardiovascular solutions in workplace health programs. The Company’s DNA-based blood tests require no additional infrastructure, and position Cardio Diagnostics to integrate seamlessly into onsite clinic settings. Implementation at employer organizations with an onsite clinic is an approach which enhances the accessibility of advanced cardiovascular diagnostics while meeting employers' demands for cost-effective, high-impact health solutions for their workforce.

Meesha Dogan, PhD, CEO and Co-Founder of Cardio Diagnostics, emphasized the company's ability to help radically improve workplace health, "we are excited to partner with innovative employers and bring precision cardiovascular medicine directly to employees at work. By expanding our cutting-edge diagnostics into onsite clinics, we improve access to care and empower employers to actively manage cardiovascular health risks among their employees. We're excited to partner with employers to create both healthier workplaces and, in turn, a more productive workforce."

About Cardio Diagnostics

Cardio Diagnostics is a pioneering company in AI-powered precision cardiovascular medicine, committed to making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company leverages a proprietary AI-driven Integrated Genetic-Epigenetic Engine ("Core Technology") to develop and commercialize clinical tests aimed at improving the prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on results are discussed in the Current Report on Form 10-K for the period ended December 31, 2023, and Form 10-Q for the period ended March 31, 2024 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625441055/en/